Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11535341rdf:typepubmed:Citationlld:pubmed
pubmed-article:11535341lifeskim:mentionsumls-concept:C0035236lld:lifeskim
pubmed-article:11535341lifeskim:mentionsumls-concept:C0033684lld:lifeskim
pubmed-article:11535341lifeskim:mentionsumls-concept:C0028948lld:lifeskim
pubmed-article:11535341lifeskim:mentionsumls-concept:C0042196lld:lifeskim
pubmed-article:11535341lifeskim:mentionsumls-concept:C0332466lld:lifeskim
pubmed-article:11535341lifeskim:mentionsumls-concept:C0056912lld:lifeskim
pubmed-article:11535341lifeskim:mentionsumls-concept:C1518896lld:lifeskim
pubmed-article:11535341lifeskim:mentionsumls-concept:C0332256lld:lifeskim
pubmed-article:11535341lifeskim:mentionsumls-concept:C0439133lld:lifeskim
pubmed-article:11535341lifeskim:mentionsumls-concept:C1522673lld:lifeskim
pubmed-article:11535341pubmed:issue32lld:pubmed
pubmed-article:11535341pubmed:dateCreated2001-9-5lld:pubmed
pubmed-article:11535341pubmed:abstractTextThe feasibility of using oligodeoxynucleotides (ODN) containing unmethylated CpG motifs as parenteral adjuvants for subunit vaccines against RSV was tested in BALB/c mice. Compared with immunization with natural F protein adsorbed to aluminum hydroxide (F/AlOH) adjuvant alone, coadministration of F/AlOH with CpG ODN resulted in statistically significant increases in serum neutralization titers, an enhanced generation of splenic antigen-dependent killer cell precursors, and accelerated clearance of infectious virus from lungs 4 days after challenge. The statistically significant increases in serum IFNgamma and anti-F protein IgG2a titers, and significantly diminished pulmonary IL-5 and eosinophilia after challenge indicated that CpG ODN enhanced the ability of F/AlOH to elicit type 1 immune responses. F protein-specific serum IgE titers were also reduced. Further analysis of pulmonary inflammatory cells demonstrated an expansion of CD8(+) T cells, relative to the CD4(+) T cell compartment. The potency of CpG ODN was not adversely affected in gene knockout mice devoid of the p35 chain of the IL-12 heterodimer. Taken together, the results suggest a novel formulation for naïve recipients of F protein-based subunit vaccines that does not result in a type 2 phenotype.lld:pubmed
pubmed-article:11535341pubmed:languageenglld:pubmed
pubmed-article:11535341pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11535341pubmed:citationSubsetIMlld:pubmed
pubmed-article:11535341pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11535341pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11535341pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11535341pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11535341pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11535341pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11535341pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11535341pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11535341pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11535341pubmed:statusMEDLINElld:pubmed
pubmed-article:11535341pubmed:monthSeplld:pubmed
pubmed-article:11535341pubmed:issn0264-410Xlld:pubmed
pubmed-article:11535341pubmed:authorpubmed-author:SmithJ DJDlld:pubmed
pubmed-article:11535341pubmed:authorpubmed-author:HancockG EGElld:pubmed
pubmed-article:11535341pubmed:authorpubmed-author:IbraghimovA...lld:pubmed
pubmed-article:11535341pubmed:authorpubmed-author:HeersK MKMlld:pubmed
pubmed-article:11535341pubmed:authorpubmed-author:ScheuerC ACAlld:pubmed
pubmed-article:11535341pubmed:authorpubmed-author:PryharskiK...lld:pubmed
pubmed-article:11535341pubmed:issnTypePrintlld:pubmed
pubmed-article:11535341pubmed:day14lld:pubmed
pubmed-article:11535341pubmed:volume19lld:pubmed
pubmed-article:11535341pubmed:ownerNLMlld:pubmed
pubmed-article:11535341pubmed:authorsCompleteYlld:pubmed
pubmed-article:11535341pubmed:pagination4874-82lld:pubmed
pubmed-article:11535341pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:11535341pubmed:meshHeadingpubmed-meshheading:11535341...lld:pubmed
pubmed-article:11535341pubmed:meshHeadingpubmed-meshheading:11535341...lld:pubmed
pubmed-article:11535341pubmed:meshHeadingpubmed-meshheading:11535341...lld:pubmed
pubmed-article:11535341pubmed:meshHeadingpubmed-meshheading:11535341...lld:pubmed
pubmed-article:11535341pubmed:meshHeadingpubmed-meshheading:11535341...lld:pubmed
pubmed-article:11535341pubmed:meshHeadingpubmed-meshheading:11535341...lld:pubmed
pubmed-article:11535341pubmed:meshHeadingpubmed-meshheading:11535341...lld:pubmed
pubmed-article:11535341pubmed:meshHeadingpubmed-meshheading:11535341...lld:pubmed
pubmed-article:11535341pubmed:meshHeadingpubmed-meshheading:11535341...lld:pubmed
pubmed-article:11535341pubmed:meshHeadingpubmed-meshheading:11535341...lld:pubmed
pubmed-article:11535341pubmed:meshHeadingpubmed-meshheading:11535341...lld:pubmed
pubmed-article:11535341pubmed:meshHeadingpubmed-meshheading:11535341...lld:pubmed
pubmed-article:11535341pubmed:meshHeadingpubmed-meshheading:11535341...lld:pubmed
pubmed-article:11535341pubmed:meshHeadingpubmed-meshheading:11535341...lld:pubmed
pubmed-article:11535341pubmed:meshHeadingpubmed-meshheading:11535341...lld:pubmed
pubmed-article:11535341pubmed:meshHeadingpubmed-meshheading:11535341...lld:pubmed
pubmed-article:11535341pubmed:meshHeadingpubmed-meshheading:11535341...lld:pubmed
pubmed-article:11535341pubmed:meshHeadingpubmed-meshheading:11535341...lld:pubmed
pubmed-article:11535341pubmed:meshHeadingpubmed-meshheading:11535341...lld:pubmed
pubmed-article:11535341pubmed:meshHeadingpubmed-meshheading:11535341...lld:pubmed
pubmed-article:11535341pubmed:meshHeadingpubmed-meshheading:11535341...lld:pubmed
pubmed-article:11535341pubmed:meshHeadingpubmed-meshheading:11535341...lld:pubmed
pubmed-article:11535341pubmed:meshHeadingpubmed-meshheading:11535341...lld:pubmed
pubmed-article:11535341pubmed:meshHeadingpubmed-meshheading:11535341...lld:pubmed
pubmed-article:11535341pubmed:meshHeadingpubmed-meshheading:11535341...lld:pubmed
pubmed-article:11535341pubmed:meshHeadingpubmed-meshheading:11535341...lld:pubmed
pubmed-article:11535341pubmed:meshHeadingpubmed-meshheading:11535341...lld:pubmed
pubmed-article:11535341pubmed:meshHeadingpubmed-meshheading:11535341...lld:pubmed
pubmed-article:11535341pubmed:meshHeadingpubmed-meshheading:11535341...lld:pubmed
pubmed-article:11535341pubmed:meshHeadingpubmed-meshheading:11535341...lld:pubmed
pubmed-article:11535341pubmed:year2001lld:pubmed
pubmed-article:11535341pubmed:articleTitleCpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV).lld:pubmed
pubmed-article:11535341pubmed:affiliationDepartment of Immunology Research, Wyeth-Lederle Vaccines, 211 Bailey Road, West Henrietta, NY 14586, USA. hancocg@war.wyeth.comlld:pubmed
pubmed-article:11535341pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11535341lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11535341lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11535341lld:pubmed